High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
PubMed
25402418
DOI
10.1038/bmt.2014.262
PII: bmt2014262
Knihovny.cz E-zdroje
- MeSH
- akutní myeloidní leukemie krev terapie MeSH
- antigeny CD34 metabolismus MeSH
- autologní transplantace MeSH
- dospělí MeSH
- indukce remise MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mobilizace hematopoetických kmenových buněk metody MeSH
- přežití bez známek nemoci MeSH
- příprava pacienta k transplantaci metody MeSH
- recidiva MeSH
- rizikové faktory MeSH
- transplantace hematopoetických kmenových buněk metody MeSH
- transplantace kostní dřeně metody MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- antigeny CD34 MeSH
The faster hematopoietic recovery after autologous peripheral blood SCT (APBSCT) in patients with AML may be offset by an increased relapse risk as compared with autologous BMT (ABMT). The EORTC and GIMEMA Leukemia Groups conducted a trial (AML-10) in which they compared, as second randomization, APBSCT and ABMT in first CR patients without an HLA compatible donor. A total of 292 patients were randomized. The 5-year DFS rate was 41% in the APBSCT arm and 46% in the ABMT arm with a hazard ratio (HR) of 1.17; 95% confidence interval=0.85-1.59; P=0.34. The 5-year cumulative relapse incidence was 56% vs 49% (P=0.26), and the 5-year OS 50% and 55% (P=0.6) in the APBSCT and ABMT groups, respectively. APBSCT was associated with significantly faster recovery of neutrophils and platelets, shorter duration of hospitalization, reduced need of transfusion packed RBC and less days of intravenous antibiotics. In both treatment groups, higher numbers of mobilized CD34+ cells were associated with a significantly higher relapse risk irrespective of the treatment given after the mobilization. Randomization between APBSCT and ABMT did not result in significantly different outcomes in terms of DFS, OS and relapse incidence.
A O R N San Giuseppe Moscati Avelino Italy
EORTC Headquarters Brussels Belgium
Federico 2 University Napoli Italy
Gustave Roussy Comprehensive Cancer Center Villejuif France
Institute Hematology Prague Czech Republic
Leiden University Medical Center Leiden The Netherlands
Necker Institut Curie Paris France
Radboud University Nijmegen Medical Center Nijmegen The Netherlands
Sapienza University Roma Italy
Tor Vergata University Hospital Roma Italy
Zobrazit více v PubMed
Leukemia. 2003 Jan;17(1):68-75 PubMed
Blood. 2007 May 1;109(9):3658-66 PubMed
Blood. 2011 May 19;117(20):5306-13 PubMed
N Engl J Med. 1995 Jan 26;332(4):217-23 PubMed
Semin Hematol. 2007 Oct;44(4):259-66 PubMed
Leukemia. 2004 Aug;18(8):1380-90 PubMed
Br J Haematol. 2005 Jan;128(1):59-65 PubMed
J Clin Oncol. 2011 Feb 1;29(4):369-77 PubMed
Bone Marrow Transplant. 1996 Jun;17(6):993-1001 PubMed
Blood. 2011 Dec 1;118(23):6037-42 PubMed
Blood. 1997 Oct 15;90(8):2978-86 PubMed
J Clin Oncol. 2009 Aug 20;27(24):3987-93 PubMed
Blood. 2010 Jan 21;115(3):453-74 PubMed
Bone Marrow Transplant. 1995 Apr;15(4):652-3 PubMed
J Clin Oncol. 2011 Feb 10;29(5):487-94 PubMed
Bone Marrow Transplant. 1999 Jun;23(12):1279-82 PubMed
J Clin Oncol. 2009 Nov 10;27(32):5397-403 PubMed
Lancet. 1998 Mar 7;351(9104):700-8 PubMed
Blood. 2011 Jun 16;117(24):6411-6 PubMed
Int J Mol Epidemiol Genet. 2010;1(3):201-7 PubMed
Blood. 2010 Oct 28;116(17):3157-62 PubMed
Leukemia. 2003 Jan;17(1):60-7 PubMed
